Alyson K Zalta1,2, Karyna Bravo2, Zerbrina Valdespino-Hayden2,3, Mark H Pollack2, Helen J Burgess2,4. 1. Department of Psychological Science, University of California, Irvine, Irvine, California. 2. Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, Illinois. 3. Department of Psychology, Montclair State University, Montclair, New Jersey. 4. Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Evidence-based treatments for post-traumatic stress disorder (PTSD) have poor uptake and remission rates, suggesting that alternative treatments are needed. Morning bright light may be an effective treatment for PTSD given its established effects on mood and sleep, however, there are no published trials. METHODS: We conducted a placebo-controlled pilot trial of a wearable light device, the Re-timer®, for individuals with probable PTSD. Individuals were randomly assigned to the active Re-timer® (n = 9) or a placebo Re-timer® dimmed with neutral density filters (n = 6). Participants self-administered the treatment at home 1 hr each morning over 4 weeks. PTSD and depression symptoms were assessed at pre- and post-treatment. RESULTS: The Re-timer® was well tolerated and the perceived benefit was high, though treatment adherence was only moderate. Those in the active group were more likely to achieve a minimal clinically important change in PTSD and depression symptoms and had larger symptom reductions than those in the placebo group CONCLUSIONS: A wearable morning light treatment was acceptable and feasible for patients with probable PTSD. This study provides initial proof-of-concept that light treatment can improve PTSD. A larger trial is warranted to establish treatment efficacy. NCT#: 03513848.
RCT Entities:
BACKGROUND: Evidence-based treatments for post-traumatic stress disorder (PTSD) have poor uptake and remission rates, suggesting that alternative treatments are needed. Morning bright light may be an effective treatment for PTSD given its established effects on mood and sleep, however, there are no published trials. METHODS: We conducted a placebo-controlled pilot trial of a wearable light device, the Re-timer®, for individuals with probable PTSD. Individuals were randomly assigned to the active Re-timer® (n = 9) or a placebo Re-timer® dimmed with neutral density filters (n = 6). Participants self-administered the treatment at home 1 hr each morning over 4 weeks. PTSD and depression symptoms were assessed at pre- and post-treatment. RESULTS: The Re-timer® was well tolerated and the perceived benefit was high, though treatment adherence was only moderate. Those in the active group were more likely to achieve a minimal clinically important change in PTSD and depression symptoms and had larger symptom reductions than those in the placebo group CONCLUSIONS: A wearable morning light treatment was acceptable and feasible for patients with probable PTSD. This study provides initial proof-of-concept that light treatment can improve PTSD. A larger trial is warranted to establish treatment efficacy. NCT#: 03513848.
Authors: Jennifer H Wortmann; Alexander H Jordan; Frank W Weathers; Patricia A Resick; Katherine A Dondanville; Brittany Hall-Clark; Edna B Foa; Stacey Young-McCaughan; Jeffrey S Yarvis; Elizabeth A Hembree; Jim Mintz; Alan L Peterson; Brett T Litz Journal: Psychol Assess Date: 2016-01-11
Authors: Annette van Maanen; Anne Marie Meijer; Kristiaan B van der Heijden; Frans J Oort Journal: Sleep Med Rev Date: 2015-09-09 Impact factor: 11.609
Authors: Lehana Thabane; Jinhui Ma; Rong Chu; Ji Cheng; Afisi Ismaila; Lorena P Rios; Reid Robson; Marroon Thabane; Lora Giangregorio; Charles H Goldsmith Journal: BMC Med Res Methodol Date: 2010-01-06 Impact factor: 4.615
Authors: David P Cenkner; Helen J Burgess; Brooke Huizenga; Elizabeth R Duval; Hyungjin Myra Kim; K Luan Phan; Israel Liberzon; Heide Klumpp; James Abelson; Adam Horwitz; Ann Mooney; Greta B Raglan; Alyson K Zalta Journal: PLoS One Date: 2022-06-08 Impact factor: 3.752
Authors: Jeanne F Duffy; Sabra M Abbott; Helen J Burgess; Stephanie J Crowley; Jonathan S Emens; Lawrence J Epstein; Karen L Gamble; Brant P Hasler; David A Kristo; Roneil G Malkani; Shadab A Rahman; S Justin Thomas; James K Wyatt; Phyllis C Zee; Elizabeth B Klerman Journal: Sleep Date: 2021-05-14 Impact factor: 5.849
Authors: John R Vanuk; Edward F Pace-Schott; Ayla Bullock; Simon Esbit; Natalie S Dailey; William D S Killgore Journal: Front Behav Neurosci Date: 2022-09-12 Impact factor: 3.617
Authors: Emily J Ricketts; Helen J Burgess; Gabrielle E Montalbano; Meredith E Coles; Joseph F McGuire; Hardian Thamrin; Dana L McMakin; James T McCracken; Mary A Carskadon; John Piacentini; Christopher S Colwell Journal: J Neurol Date: 2021-06-13 Impact factor: 4.849